Literature DB >> 3292789

Molecular characterization of gag proteins from simian immunodeficiency virus (SIVMne).

L E Henderson1, R E Benveniste, R Sowder, T D Copeland, A M Schultz, S Oroszlan.   

Abstract

A simian immunodeficiency virus (SIV) designated SIVMne was isolated from a pig-tailed macaque with lymphoma housed at the University of Washington Regional Primate Research Center, Seattle. To better establish the relationship of SIVMne to other immunodeficiency viruses, we purified and determined the partial amino acid sequences of six structural proteins (p1, p2, p6, p8, p16, and p28) from SIVMne and compared these amino acid sequences to the translated nucleotide sequences of SIVMac and human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2). A total of 125 residues of SIVMne amino acid sequence were compared to the predicted amino acid sequences of the gag precursors of SIV and HIVs. In the compared regions 92% of the SIVMne amino acids were identical to predicted residues of SIVMac, 83% were identical to predicted residues of HIV-2, and 41% were identical to predicted residues of HIV-1. These data reveal that the six SIVMne proteins are proteolytic cleavage products of the gag precursor (Pr60gag) and that their order in the structure of Pr60gag is p16-p28-p2-p8-p1-p6. Rabbit antisera prepared against purified p28 and p16 were shown to cross-react with proteins of 60, 54, and 47 kilodaltons present in the viral preparation and believed to be SIVMne Pr60gag and intermediate cleavage products, respectively. SIVMne p16 was shown to contain covalently bound myristic acid, and p8 was identified as a nucleic acid-binding protein. The high degree of amino acid sequence homology between SIVs and HIV-2 around proven proteolytic cleavage sites in SIV Pr60gag suggests that proteolytic processing of the HIV-2 gag precursor is probably very similar to processing of the SIV gag precursor. Peptide bonds cleaved during proteolytic processing of the SIV gag precursor were similar to bonds cleaved during processing of HIV-1 gag precursors, suggesting that the SIV and HIV viral proteases have similar cleavage site specificities.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3292789      PMCID: PMC253688     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Two efficient ribosomal frameshifting events are required for synthesis of mouse mammary tumor virus gag-related polyproteins.

Authors:  T Jacks; K Townsley; H E Varmus; J Majors
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

2.  Isolation of a new human retrovirus from West African patients with AIDS.

Authors:  F Clavel; D Guétard; F Brun-Vézinet; S Chamaret; M A Rey; M O Santos-Ferreira; A G Laurent; C Dauguet; C Katlama; C Rouzioux
Journal:  Science       Date:  1986-07-18       Impact factor: 47.728

3.  Human T-lymphotropic virus type 4 and the human immunodeficiency virus in West Africa.

Authors:  P J Kanki; S M'Boup; D Ricard; F Barin; F Denis; C Boye; L Sangare; K Travers; M Albaum; R Marlink
Journal:  Science       Date:  1987-05-15       Impact factor: 47.728

4.  Genome organization and transactivation of the human immunodeficiency virus type 2.

Authors:  M Guyader; M Emerman; P Sonigo; F Clavel; L Montagnier; M Alizon
Journal:  Nature       Date:  1987 Apr 16-22       Impact factor: 49.962

5.  Chemical and immunological characterizations of equine infectious anemia virus gag-encoded proteins.

Authors:  L E Henderson; R C Sowder; G W Smythers; S Oroszlan
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

6.  Isolation of a lentivirus from a macaque with lymphoma: comparison with HTLV-III/LAV and other lentiviruses.

Authors:  R E Benveniste; L O Arthur; C C Tsai; R Sowder; T D Copeland; L E Henderson; S Oroszlan
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

7.  Isolation of a T-lymphotropic retrovirus from naturally infected sooty mangabey monkeys (Cercocebus atys).

Authors:  P N Fultz; H M McClure; D C Anderson; R B Swenson; R Anand; A Srinivasan
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

8.  Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses.

Authors:  G Franchini; C Gurgo; H G Guo; R C Gallo; E Collalti; K A Fargnoli; L F Hall; F Wong-Staal; M S Reitz
Journal:  Nature       Date:  1987 Aug 6-12       Impact factor: 49.962

9.  Humoral immune responses to T cell tropic retrovirus simian T lymphotropic virus type III in monkeys with experimentally induced acquired immune deficiency-like syndrome.

Authors:  M Kannagi; M Kiyotaki; R C Desrosiers; K A Reimann; N W King; L M Waldron; N L Letvin
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

10.  The genome organization of STLV-3 is similar to that of the AIDS virus except for a truncated transmembrane protein.

Authors:  V Hirsch; N Riedel; J I Mullins
Journal:  Cell       Date:  1987-05-08       Impact factor: 41.582

View more
  61 in total

1.  Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost.

Authors:  R J Gorelick; R E Benveniste; J D Lifson; J L Yovandich; W R Morton; L Kuller; B M Flynn; B A Fisher; J L Rossio; M Piatak; J W Bess; L E Henderson; L O Arthur
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  A human nuclear shuttling protein that interacts with human immunodeficiency virus type 1 matrix is packaged into virions.

Authors:  K Gupta; D Ott; T J Hope; R F Siliciano; J D Boeke
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: posttranslational modifications, proteolytic processings, and complete amino acid sequences.

Authors:  L E Henderson; M A Bowers; R C Sowder; S A Serabyn; D G Johnson; J W Bess; L O Arthur; D K Bryant; C Fenselau
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

4.  Mutational analysis of human immunodeficiency virus type 1 protease suggests functional homology with aspartic proteinases.

Authors:  D D Loeb; C A Hutchison; M H Edgell; W G Farmerie; R Swanstrom
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

5.  Validating the vitality strategy for fighting drug resistance.

Authors:  Nidhi Singh; Maria P Frushicheva; Arieh Warshel
Journal:  Proteins       Date:  2012-01-31

6.  Replication of human immunodeficiency virus 1 and Moloney murine leukemia virus is inhibited by different heteroatom-containing analogs of myristic acid.

Authors:  M L Bryant; R O Heuckeroth; J T Kimata; L Ratner; J I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

7.  Phosphorylation and proteolytic cleavage of gag proteins in budded simian immunodeficiency virus.

Authors:  Sarah M Rue; Jason W Roos; Patrick M Tarwater; Janice E Clements; Sheila A Barber
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

8.  Deletion of sequences upstream of the proteinase improves the proteolytic processing of human immunodeficiency virus type 1.

Authors:  K Partin; G Zybarth; L Ehrlich; M DeCrombrugghe; E Wimmer; C Carter
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

9.  Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease.

Authors:  Steve C Pettit; Gavin J Henderson; Celia A Schiffer; Ronald Swanstrom
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.

Authors:  S C Pettit; M D Moody; R S Wehbie; A H Kaplan; P V Nantermet; C A Klein; R Swanstrom
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.